Dapoflit B Tablet contains Dapagliflozin 10mg and Bisoprolol 5mg, a dual-action formulation designed to manage type 2 diabetes along with hypertension, supporting overall cardiovascular and renal health. Its combination ensures better patient compliance by reducing pill burden.
The tablet works by controlling blood glucose levels through Dapagliflozin while Bisoprolol helps regulate blood pressure and cardiac function, providing a synergistic approach for patients with coexisting conditions. Its consistent efficacy makes it a preferred choice among doctors managing complex cardio-metabolic cases.
For suppliers, Dapoflit B Tablet represents a high-demand product in the chronic therapy segment, offering reliable repeat business and strong prescription potential. Its dual-action nature makes it an attractive option for cardiologists, endocrinologists, and general practitioners.
Including Dapoflit B in your portfolio helps distributors expand into the growing market of cardio-metabolic therapy, increase visibility among healthcare providers, and achieve better turnover with a clinically relevant, trusted formulation.
Possible side effects include dizziness, hypotension, urinary tract infections, increased urination, fatigue, and mild gastrointestinal discomfort. Rarely, severe hypoglycemia, electrolyte imbalance, or allergic reactions may occur.
Dapoflit B Tablet is indicated for the management of type 2 diabetes mellitus, particularly in patients with cardiovascular risk, and for controlling hypertension and heart rate in patients with coexisting heart conditions. It helps reduce blood glucose levels and supports cardiac function.
Use under medical supervision. Not recommended in patients with severe kidney or liver impairment, hypotension, or known hypersensitivity to the components. Monitor blood sugar and blood pressure regularly.
Store in a cool, dry place below 25°C, away from light and moisture. Keep out of reach of children.